Jazz Pharmaceuticals PLC

JAZZ remains in a corrective structural repair phase after failing beneath the 9-EMA, 20-EMA, and 50-SMA, with a bearish pivot point confirming downside control. A minor exhaustion wick hints at a possible relief bounce, but any rally into the moving averages is likely to stall, reinforcing a medium-term bearish bias. Exposure should be trimmed now, awaiting a better entry on a clear stabilization or reclaim of key averages, while acknowledging that the long-term uptrend above the 200-SMA remains intact.

• ↑Q2 revenue hit $1.2B (+16% YoY), with ZyWave at $471M (+13%).
• ↑Epidiolex achieved blockbuster status, delivering $292M in Q2 and $1.1B expected in 2025.
• ↓High-sodium generics may erode ZyWave volumes as payers tighten utilization.